Physician profile
Catherine Delay
NPI 1376741223
$496.53
in general payments reported to CMS, 2019-2025
12 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.59 · 2022: $38.56 · 2023: $78.28 · 2024: $212 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $424.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $75.26 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $70.63 | 2024-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.87 | 2023-2024 | Xifaxan |
| Exact Sciences Corporation | $57.12 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cranial Technologies, INC | $43.24 | 2023-2025 | Doc Band |
| Scilex Pharmaceuticals INC. | $36.39 | 2023-2025 | Ztlido |
| Astrazeneca Pharmaceuticals Lp | $35.99 | 2022-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.65 | 2021-2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $28.14 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $21.56 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.43 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Delay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.